ISS I: Exploring a Non-Chemotherapy Treatment Option for Patients with Certain Types of Advanced Endometrial Carcinoma
Supported by: Eisai, Inc.
Date: Saturday, March 25th, 11:15am – 12:45pm
Location: Ballroom A
Description: Review the epidemiology of uterine cancer. Review the efficacy and safety profile of a treatment option for patients with certain types of advanced endometrial carcinoma. Discuss the monitoring and management of certain adverse reactions (AR) associated with this treatment option– Includes median time to AR onset data.
Speakers:
Krishnansu S. Tewari, MD, UCI Health, Division of Gynecologic Oncology, Obstetrics & Gynecology, School of Medicine Director, Division of Gynecologic Oncology, Obstetrics & Gynecology, School of Medicine
No Pre-Registration Required
ISS II: Immunotherapy as a Treatment Cornerstone for Advanced Endometrial Cancer: Personalizing Patient Care
This CME/MOC activity is provided by PVI, PeerView Institute for Medical Education. This activity is supported by independent educational grants from AstraZeneca, Eisai Inc., GSK, and Merck & Co., Inc.
Date: Saturday, March 25th, 11:15am – 12:45pm
Location: Ballroom B
Description: This unique interactive event is designed to offer learners an in-depth look at the mechanistic rationale, latest clinical evidence, and ongoing research on checkpoint inhibitors and other innovative strategies in endometrial cancer management (MasterClass), as well as practical guidance on the safe and effective integration of these treatments in different clinical settings (Practicum), including the appropriate use of diagnostic testing for relevant biomarkers, recommendations for adverse event management, opportunities for clinical trial enrollment, and strategies for patient/caregiver education to help patients become well-informed participants in their own care.
Speakers:
David M. O’Malley, MD, The James Cancer Hospital and Solove Research Institute, The Ohio State University College of Medicine, Columbus, Ohio
Ana Oaknin, MD, PhD. Vall d’Hebron University Hospital. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Bhavana Pothuri, MD, MS, New York University Langone Health, NYU Grossman School of Medicine, New York, New York
REGISTER Now
ISS III: Maintenance Therapy in Advanced Ovarian Cancer: Results from Key Clinical Trials
Supported by: AstraZeneca
Date: Saturday, March 25th, 11:15am – 12:45pm
Location: Ballroom C
Description: Describes the need for first-line maintenance of advanced ovarian cancer following response to first-line chemotherapy• Discusses the data from PAOLA-1 demonstrating the efficacy and safety of LYNPARZA in combination with bevacizumab as first-line maintenance treatment for HRD-positive advanced ovarian cancer• Highlights the data from SOLO-1 supporting LYNPARZA first-line maintenance therapy as the standard of care in BRCAm advanced ovarian cancer.
Speaker: Bradley Monk, MD, University of Arizona College of Medicine, Professor, Obstetrics & Gynecologic
No Pre-Registration Required
ISS IV: A New Targeted Treatment for Ovarian Cancer
Supported by: ImmunoGen
Date: Saturday, March 25th, 11:15am – 12:45pm
Location: Ballroom D
Description: Learn about an advancement in targeting ovarian cancer. Explore clinical evidence of a newly approved therapy. Discuss biomarker testing and patient management.
Speakers:
Gottfried E. Konecny, MD, University of California, Los Angeles, Professor of Medicine and Ob/Gyn, Director, Medical Gynecologic Oncology
Courtney Arn, APRN-CNP, The Ohio State University
Grace Lytle, OD, MS, Executive Ocular Medical Director, ImmunoGen
No Pre-Registration Required
ISS V: dMMR Recurrent or Advanced Endometrial Cancer Illuminated
Supported by: GSK
Date: Sunday, March 26, 11:45am-1:15pm
Location: Ballroom A
Description: This presentation will discuss JEMPERLI (dostarlimab-gxly) injection, indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any setting. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s)The focus of this presentation is the approval in endometrial cancer
Speakers: John Chan, MD Gynecologic Oncology Director, Sutter Health
No Pre-Registration Required
ISS VI:Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Ovarian Cancers
Supported by: This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, ImmunoGen Inc, Merck, Mersana Therapeutics Inc, and Novocure Inc.
CME accredited by Research To Practice.
Date: Sunday, March 26, 11:45am-1:15pm, hot lunch buffet offered 30 minutes prior
Location: Ballroom B – Level 1 (Tampa Convention Center)
Description:
This CME symposium will focus on the current and future management of ovarian cancer. Dr. Neil Love and his CME group, Research To Practice (RTP), have invited four clinical investigators to serve as faculty for this program and one of these participating faculty will also serve as the program moderator. In addition, 3 US-based community-based general gynecologic and medical oncologists will participate in a one-on-one interview with Dr. Love during which they present current cases from their practices for which they would seek input or a second opinion from clinical investigators. Excerpts from each video recorded interview will be selected for presentation during the program.
The agenda for the symposium will be divided into four modules. To begin each module, the moderator will introduce select video excerpts from the recorded case presentations and ask the other faculty members to comment on the treatment decision-making for the case presented. The faculty members will also be called upon to reflect on the own clinical experiences caring for similar patients and their interpretation of available data. Following these discussions, each faculty will deliver a presentation focused on reviewing relevant scientific knowledge, data sets and research related to the topics and cases under review.
To make the event even more relevant, both in-person and virtual attendees will be able to participate in surveys related to the topics and cases that will be discussed. Clinicians will also be encouraged to submit additional questions as well as their own cases via the networked iPads in the meeting room or via our Zoom virtual platform.
Speakers:
Mansoor Raza Mirza, MD
Copenhagen University Hospital
Amit M Oza, MD
University of Toronto
Richard T Penson, MD, MRCP
Massachusetts General Hospital
Moderator:
Joyce F Liu, MD, MPH
Dana-Farber Cancer Institute
REGISTER Now